Evidence map›Paper›PMID 36682583›Full record

ArticleBiochimica et biophysica acta. Gene regulatory mechanisms2023

DNA methylation of the promoter region at the CREB1 binding site is a mechanism for the epigenetic regulation of brain-specific PKMζ.

Dimitrius Tansini Pramio, Felipe Monteleone Vieceli, Elisa Varella-Branco, Carolina Purcell Goes, Gerson Shigeru Kobayashi, Diogo Vieira da Silva Pelegrina, Beatriz Caroline de Moraes, Aicha El Allam, Bony De Kumar, Gabriel Jara and 10 more

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Gene regulatory mechanisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Dimitrius Tansini PramioDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil.
Felipe Monteleone VieceliDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil.
Elisa Varella-BrancoInstituto de Biociências, Universidade de São Paulo, SP, Brazil.
Carolina Purcell GoesDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil; Laboratory of Neuromodulation of Experimental Pain, Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, SP, Brazil.
Gerson Shigeru KobayashiInstituto de Biociências, Universidade de São Paulo, SP, Brazil.
Diogo Vieira da Silva PelegrinaDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil.
Beatriz Caroline de MoraesDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil.
Aicha El AllamDepartment of Neurology, Yale School of Medicine, New Haven, CT, USA.
Bony De KumarYale Center for Genome Analysis, New Haven, CT, USA.
Gabriel JaraBrazilian Center for Research in Energy and Materials (CNPEM), Brazilian National Biosciences Laboratory (LNBio) Campinas, SP, Brazil.
José Marcelo FarfelTraumatology and Orthopedy Department, Faculdade de Medicina, Universidade de São Paulo, SP, Brazil; Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Health Sciences Program, Instituto de Assistência Medica ao Servidor Público do Estado (IAMSPE), SP, Brazil.
David Alan BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
Somanath KunduDepartment of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.
Mariano S ViapianoDepartment of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY, USA.
Eduardo Moraes ReisDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil.
Paulo Sergio Lopes de OliveiraBrazilian Center for Research in Energy and Materials (CNPEM), Brazilian National Biosciences Laboratory (LNBio) Campinas, SP, Brazil.
Maria Rita Dos Santos E Passos-BuenoInstituto de Biociências, Universidade de São Paulo, SP, Brazil.
Carla V RothlinDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA; Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA.
Sourav GhoshDepartment of Neurology, Yale School of Medicine, New Haven, CT, USA; Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA. Electronic address: sourav.ghosh@yale.edu.
Deborah SchechtmanDepartamento de Bioquímica, Instituto de Química, Universidade de São Paulo, SP, Brazil. Electronic address: deborah@iq.usp.br.
Universidade de São Paulo · BRYale University · USSUNY Upstate Medical University · USBrazilian Biosciences National Laboratory · BRBrazilian Center for Research in Energy and Materials · BRRush University Medical Center · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7M
Pathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6M
Exploring the Role of the Brain Epigenome: Cognitive Decline and Life ExperiencesR01AG036042 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2009 to 2013
$4.1M
Apical-basal polarity signaling in glioblastomaR01CA149258 · NCI · YALE UNIVERSITY · PI GHOSH, SOURAV · 2010 to 2014
$1.7M
NCI NIH HHS R01 CA149258NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG036042NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG061356
6 · The paper itself

Abstract

Protein kinase M zeta, PKMζ, is a brain enriched kinase with a well characterized role in Long-Term Potentiation (LTP), the activity-dependent strengthening of synapses involved in long-term memory formation. However, little is known about the molecular mechanisms that maintain the tissue specificity of this kinase. Here, we characterized the epigenetic factors, mainly DNA methylation, regulating PKMζ expression in the human brain. The PRKCZ gene has an upstream promoter regulating Protein kinase C ζ (PKCζ), and an internal promoter driving PKMζ expression. A demethylated region, including a canonical CREB binding site, situated at the internal promoter was only observed in human CNS tissues. The induction of site-specific hypermethylation of this region resulted in decreased CREB1 binding and downregulation of PKMζ expression. Noteworthy, CREB binding sites were absent in the upstream promoter of PRKCZ locus, suggesting a specific mechanism for regulating PKMζ expression. These observations were validated using a system of human neuronal differentiation from induced pluripotent stem cells (iPSCs). CREB1 binding at the internal promoter was detected only in differentiated neurons, where PKMζ is expressed. The same epigenetic mechanism in the context of CREB binding site was identified in other genes involved in neuronal differentiation and LTP. Additionally, aberrant DNA hypermethylation at the internal promoter was observed in cases of Alzheimer's disease, correlating with decreased expression of PKMζ in patient brains. Altogether, we present a conserved epigenetic mechanism regulating PKMζ expression and other genes enhanced in the CNS with possible implications in neuronal differentiation and Alzheimer's disease.

Indexed as

Alzheimer DiseaseBrainCyclic AMP Response Element-Binding ProteinDNA MethylationEpigenesis, GeneticHumansLong-Term PotentiationCREB1 protein, humanCyclic AMP Response Element-Binding ProteinAlzheimer's diseaseCREB1DNA methylationEpigeneticsPKMζ

Identifiers

PMID36682583
PMCPMC10037092
OpenAlexW4317530430

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.